{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 408916457
| IUPAC_name = 4-[ [4-butyl-3,5-dioxo-1,2-di(phenyl)pyrazolidin-4-yl]methoxy]-4-oxobutanoic acid
| image = suxibuzone.png

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|international|suxibuzone}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!--             / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL         / P       / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC                   / Rx-only  / Schedule I, II, III, IV, V -->
| legal_status =  
| routes_of_administration =

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number =  
| ATC_prefix = M02
| ATC_suffix = AA22
| ATC_supplemental =  {{ATCvet|M01|AA90}}
| PubChem = 5362
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = 86TDZ5WP2B
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D01289
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1414320
|  ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 5169
|  smiles = O=C(O)CCC(=O)OCC2(C(=O)N(c1ccccc1)N(C2=O)c3ccccc3)CCCC
|  StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C24H26N2O6/c1-2-3-16-24(17-32-21(29)15-14-20(27)28)22(30)25(18-10-6-4-7-11-18)26(23(24)31)19-12-8-5-9-13-19/h4-13H,2-3,14-17H2,1H3,(H,27,28)
|  StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = ONWXNHPOAGOMTG-UHFFFAOYSA-N

<!--Chemical data-->
| C=24 | H=26 | N=2 | O=6 
| molecular_weight = 438.47304 g/mol
}}

'''Suxibuzone''' is a [[analgesic]] used for joint and muscular [[pain]]. It is a prodrug of the [[nonsteroidal anti-inflammatory drug]] (NSAID) [[phenylbutazone]],<ref name="pmid7097505">{{cite journal | vauthors = Yasuda Y, Shindo T, Mitani N, Ishida N, Oono F, Kageyama T | title = Comparison of the absorption, excretion, and metabolism of suxibuzone and phenylbutazone in humans | journal = Journal of Pharmaceutical Sciences | volume = 71 | issue = 5 | pages = 565–72 | year = 1982 | pmid = 7097505 | doi = 10.1002/jps.2600710521 }}</ref> and is commonly used in horses.<ref name="pmid19927590">{{cite journal | vauthors = Sabaté D, Homedes J, Salichs M, Sust M, Monreal L | title = Multicentre, controlled, randomised and blinded field study comparing efficacy of suxibuzone and phenylbutazone in lame horses | journal = Equine Veterinary Journal | volume = 41 | issue = 7 | pages = 700–5 | year = 2009 | pmid = 19927590 | doi = 10.2746/042516409X464807 }}</ref>

==References==
{{Reflist}}


{{Anti-inflammatory and antirheumatic products}}
{{Topical products for joint and muscular pain}}

[[Category:Pyrazolidindiones]]
[[Category:Carboxylate esters]]


{{musculoskeletal-drug-stub}}